## STATUTORY RULES OF NORTHERN IRELAND

## 2014 No. 323

## The Human Medicines (Amendment) Regulations 2014

## Amendment of regulation 218

- 7.—(1) Regulation 218 (requirements for prescriptions: EEA health professionals) is amended as follows.
  - (2) For paragraph (2) substitute—
    - "(2) Condition A is that—
      - (a) the prescription is issued in an EEA State other than the United Kingdom or Switzerland; and
      - (b) the prescribing EEA health professional is legally entitled to issue a prescription of that kind in the EEA State in which the prescription is issued."
  - (3) For paragraph (3) substitute—
    - "(3) Condition B is that the prescription is signed in ink by the prescribing EEA health professional."
  - (4) For paragraph (5) substitute—
    - "(5) Condition D is that the prescription contains—
      - (a) the patient's—
        - (i) surname,
        - (ii) first names written out in full, and
        - (iii) date of birth;
      - (b) the issue date of the prescription;
      - (c) the prescribing EEA health professional's—
        - (i) surname,
        - (ii) first names written out in full,
        - (iii) professional qualifications,
        - (iv) direct contact details including—
          - (aa) email address, and
          - (bb) telephone or fax number with the appropriate international prefix,
        - (v) work address, and
        - (vi) name of the relevant member State in which that EEA health professional works; and
      - (d) details about the prescribed product, including where applicable the—
        - (i) common name of the product,
        - (ii) ii)brand name if—
          - (aa) the prescribed product is a biological medicinal product, or

- (bb) the prescribing EEA health professional deems it medically necessary for that product to be dispensed and the EEA health professional's reasons justifying the use of the branded product,
- (iii) pharmaceutical formulation (tablet, solution, etc.),
- (iv) quantity,
- (v) strength of the medicinal product as defined in Article 1 of the 2001 Directive, and
- (vi) dosage regimen."